On Oct. 8, 2020, Partnership to Improve Patient Care (PIPC) and Everylife Foundation for Rare Diseases hosted a webinar on the findings of the new Health Advances White Paper: Value for Whom? Incorporating Patient Perspectives into Value Assessment for Novel Cell and Gene Therapies. The webinar discussion focused on the use of traditional cost-effectiveness analyses to determine the “value” of innovative cell and gene therapies. The discussion also centered on some new and innovative models that are moving in a better direction and trying to truly determine value to patient
Click here to read highlights from this webinar discussion.